Huayao Li1, Chundi Gao2, Qing Liang3, Cun Liu2, Lijuan Liu4,5, Jing Zhuang4,5, Jing Yang4, Chao Zhou2,4, Fubin Feng4,6, Changgang Sun4,7. 1. College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. 2. College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. 3. Department of Basic Medical Sciences, School of Medicine, Xiamen University, Xiamen, China. 4. Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, China. 5. Department of Oncology, Affilited Hospital of Weifang Medical University, Weifang, China. 6. Department of Basic Medical Science, Qingdao University, Qingdao, China. 7. Chinese Medicine Innovation Institute, Shandong University of Traditional Chinese Medicine, Jinan, China.
Abstract
Background: Resistance to endocrine therapy has hampered clinical treatment in patients with ER-positive breast cancer (BRCA). Studies have confirmed that cryptotanshinone (CPT) has cytotoxic effects on BRCA cells and can significantly inhibit the proliferation and metastasis of ER-positive cancer cells. Methods: We analyzed the gene high-throughput data of ER-positive and negative BRCA to screen out key gene targets for ER-positive BRCA. Finally, the effects of CPT on BRCA cells (MCF-7 and MDA-MB-231) were examined, and quantitative RT-PCR was used to evaluate the expression of the key targets during CPT intervention. Results: A total of 169 differentially expressed genes were identified, and revealed that CPT affects the ER-positive BRCA cells by regulating CDK1, CCNA2, and ESR1. The overall experimental results initially show that MCF-7 cells were more sensitive to CPT than MDA-MB-231 cells, and the expression of ESR1 was not affected in the BRCA cells during CPT intervention, while the expression of CDK1 and CCNA2 were significantly down-regulated. Conclusion: CPT can inhibit the proliferation and migration of BRCA cells by regulating CDK1, CCNA2, and ESR1, especially in ER-positive BRCA samples. On the one hand, our research has discovered the possible mechanism that CPT can better interfere with ER+ BRCA; on the other hand, the combination of high-throughput data analysis and network pharmacology provides valuable information for identifying the mechanism of drug intervention in the disease.
Background: Resistance to endocrine therapy has hampered clinical treatment in patients with ER-positive breast cancer (BRCA). Studies have confirmed that cryptotanshinone (CPT) has cytotoxic effects on BRCA cells and can significantly inhibit the proliferation and metastasis of ER-positive cancer cells. Methods: We analyzed the gene high-throughput data of ER-positive and negative BRCA to screen out key gene targets for ER-positive BRCA. Finally, the effects of CPT on BRCA cells (MCF-7 and MDA-MB-231) were examined, and quantitative RT-PCR was used to evaluate the expression of the key targets during CPT intervention. Results: A total of 169 differentially expressed genes were identified, and revealed that CPT affects the ER-positive BRCA cells by regulating CDK1, CCNA2, and ESR1. The overall experimental results initially show that MCF-7 cells were more sensitive to CPT than MDA-MB-231 cells, and the expression of ESR1 was not affected in the BRCA cells during CPT intervention, while the expression of CDK1 and CCNA2 were significantly down-regulated. Conclusion:CPT can inhibit the proliferation and migration of BRCA cells by regulating CDK1, CCNA2, and ESR1, especially in ER-positive BRCA samples. On the one hand, our research has discovered the possible mechanism that CPT can better interfere with ER+ BRCA; on the other hand, the combination of high-throughput data analysis and network pharmacology provides valuable information for identifying the mechanism of drug intervention in the disease.
Authors: Alexis A Borisy; Peter J Elliott; Nicole W Hurst; Margaret S Lee; Joseph Lehar; E Roydon Price; George Serbedzija; Grant R Zimmermann; Michael A Foley; Brent R Stockwell; Curtis T Keith Journal: Proc Natl Acad Sci U S A Date: 2003-06-10 Impact factor: 11.205
Authors: R Clarke; T Skaar; K Baumann; F Leonessa; M James; J Lippman; E W Thompson; C Freter; N Brunner Journal: Breast Cancer Res Treat Date: 1994 Impact factor: 4.872
Authors: Tanya Barrett; Stephen E Wilhite; Pierre Ledoux; Carlos Evangelista; Irene F Kim; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Michelle Holko; Andrey Yefanov; Hyeseung Lee; Naigong Zhang; Cynthia L Robertson; Nadezhda Serova; Sean Davis; Alexandra Soboleva Journal: Nucleic Acids Res Date: 2012-11-27 Impact factor: 16.971
Authors: Diane M Demas; Susan Demo; Yassi Fallah; Robert Clarke; Kenneth P Nephew; Sandra Althouse; George Sandusky; Wei He; Ayesha N Shajahan-Haq Journal: Front Oncol Date: 2019-08-02 Impact factor: 6.244
Authors: Abhijit Mazumdar; William M Tahaney; Lakshmi Reddy Bollu; Graham Poage; Jamal Hill; Yun Zhang; Gordon B Mills; Powel H Brown Journal: NPJ Breast Cancer Date: 2019-07-26